bispecifics

Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
Fierce Pharma
Thu, 11/21/24 - 11:18 am
Jazz Pharma
FDA
HER2 Inhibitor
bispecifics
zanidatamab
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Fierce Biotech
Mon, 09/16/24 - 09:44 am
Bristol Myers Squibb
Immatics
bispecifics
IMA401
ESMO
After FDA rejection, Regeneron gains nod in Europe for T-cell engager odronextamab
Fierce Pharma
Mon, 08/26/24 - 11:20 am
Regeneron
Europe
FDA
Ordspono
bispecifics
T-cell engager
Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal
Fierce Biotech
Wed, 07/24/24 - 11:09 pm
Novartis
Dren Bio
cancer
bispecifics
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
Pharmaphorum
Thu, 12/14/23 - 09:34 am
Amgen
tarlatamab
small cell lung cancer
bispecifics
BiTE
solid tumors
Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings
Fierce Biotech
Tue, 10/31/23 - 10:19 am
Amgen
earnings
Teneobio
bispecifics
ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data
Fierce Biotech
Tue, 10/24/23 - 07:52 pm
AstraZeneca
cancer
oncology
bispecifics
FDA approves bispecific drug from Pfizer for multiple myeloma
BioPharma Dive
Mon, 08/14/23 - 06:44 pm
Pfizer
bispecifics
Elrexfio
Multiple Myeloma
FDA
Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal
BioSpace
Thu, 11/17/22 - 12:05 pm
Regeneron
CytomX Therapeutics
bispecifics
cancer
Veloci-Bi
drug development
AstraZeneca bets $25M on preclinical bispecific against hot target, docking in Chinese Harbour to land global rights
Fierce Biotech
Thu, 04/7/22 - 11:16 am
AstraZeneca
Harbour BioMed
bispecifics
Aptevo Soars on Reports of Complete Remission in AML
BioSpace
Tue, 11/23/21 - 08:56 pm
Aptevo
clinical trials
AML
APVO436
bispecifics
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Fierce Biotech
Tue, 11/9/21 - 10:40 am
Novartis
Xencor
bispecifics
blood cancers
Merck-partnered Janux hires CMO as its bispecifics near clinic
Fierce Biotech
Fri, 06/4/21 - 10:42 am
Janux Therapeutics
Merck
bispecifics
Roche eyes FDA filing after bispecific matches Eylea again
Fierce Biotech
Mon, 01/25/21 - 10:44 am
Roche
bispecifics
Regeneron
Eylea
clinical trials
faricimab
wet age-related macular degeneration
ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment
Fierce Biotech
Sun, 12/6/20 - 07:10 pm
ASH2020
JNJ
bispecifics
Multiple Myeloma
teclistamab
Esmo 2020 – More encouraging signs for checkpoint bispecifics
EP Vantage
Tue, 09/22/20 - 10:56 am
ESMO
bispecifics
Macrogenics
Akeso
mesothelioma
AK104
MGD019